Citizens Predicts $3.8B Revenue for BeOne Medicines in 2025 Amid Strong Clinical Results and Development Pipeline
ByAinvest
Saturday, Jan 31, 2026 4:29 am ET1min read
ONC--
Citizens reaffirms Market Outperform rating and $396 price target for BeOne Medicines, citing strong Phase 3 trial results in gastric cancer patients. The firm estimates BeOne's Brukinsa will generate $3.8 billion in revenue in 2025 and highlights a $4.1 billion cash position. Citizens views the recent share price decline as a "unique buying opportunity" in a leading hematology/oncology company.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet